Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.65  0.04  1.53%   
About 52% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Lisata Therapeutics Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Chola...
Yahoo News
over three months ago at benzinga.com         
Lisata Therapeutics Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Chola...
benzinga news
over three months ago at globenewswire.com         
Lisata Therapeutics Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Chola...
Macroaxis News: globenewswire.com
over three months ago at news.google.com         
Lisata Therapeutics gains shareholder nod for equity plan expansion By Investing.com - Investing.com...
Google News at Macroaxis
over three months ago at accesswire.com         
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors Who Suffered L...
news
over three months ago at finance.yahoo.com         
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint an...
Yahoo News
over three months ago at accesswire.com         
The Schall Law Firm Begins Probe Into Spruce Biosciences Inc And Encourages Investors With Losses To...
news
over six months ago at finance.yahoo.com         
Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial
Yahoo News
over six months ago at globenewswire.com         
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Lisata Therapeutics Stock Price Up 6.4 percent - Defense World
Google News at Macroaxis
over six months ago at investing.com         
Neurocrine Biosciences director Stephen Sherwin sells over 5.3 million in company stock
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Pioneering the Future of Medicine and Biosciences The Dr. James Morales Grant Empowers Aspiring Scho...
Yahoo News
over six months ago at finance.yahoo.com         
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Yahoo News
over six months ago at www.macroaxis.com         
Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the P...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
11/20/2024
2
Castle Biosciences director Daniel Bradbury sells 243,692 in stock
12/05/2024
3
Castle Biosciences CEO Derek Maetzold sells 160,741 in shares
12/09/2024
4
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/10/2024
5
Lisata Therapeutics Given Buy Rating at HC Wainwright
12/11/2024
6
Parse Biosciences bringt Evercode Mouse BCR auf den Markt, um die Entwicklung und Herstellung von Antikrpern fr Anwendungen in der Arzneimittelforschung zu unte...
12/12/2024
7
Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment
12/13/2024
8
Why Forte Biosciences Stock Is Trading Lower
12/16/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume